PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME
The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.
1 . A method of treating a subject having baseline fasting triglycerides of at least 2000 mg/dl comprising, administering to the subject about 1 g to about 10 g per day of a pharmaceutical composition comprising at least 96% by weight ethyl eicosapentaenoate for a period effective to reduce fasting triglycerides in the subject without substantially increasing LDL-C relative to a control subject not taking said pharmaceutical composition.
2 . The method of claim 1 wherein said period is a period effective to reduce fasting triglycerides in the subject by at least 50% without substantially increasing LDL-C relative to a control subject not taking said pharmaceutical composition.
3 . The method of claim 1 wherein said period is a period effective to reduce fasting triglycerides in the subject by at least 55% without substantially increasing LDL-C relative to a control subject not taking said pharmaceutical composition.
4 . The method of claim 1 wherein said period is about 1 to about 12 weeks.
5 . The method of claim 1 wherein said period is 12 weeks.
6 . The method of claim 1 wherein 2 g per day of the pharmaceutical composition is administered to the subject.
7 . The method of claim 1 wherein 4 g per day of the pharmaceutical composition is administered to the subject.
8 . The method of claim 1 wherein the composition is administered to the subject 1 to 4 times per day.
9 . The method of claim 8 wherein the composition is present in one or more capsules.